Results 51 to 60 of about 38,595 (290)

Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis

BMJ Open
Objective This study aimed to evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA) in reducing body mass index (BMI) and blood glucose levels in individuals with type 2 diabetes mellitus (T2DM) using the difference-in ...
Ammarin Thakkinstian, John Attia, Thunyarat Anothaisintawee, Gareth J Mckay, Sukanya Siriyotha, Panu Looareesuwan, Hataikarn Nimitphong   +6 more
doaj   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +1 more source

Long-acting GLP-1RAs

JAAPA, 2020
ABSTRACT Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and glucose regulation has led to innovative research and new treatment paradigms. The discovery of the gut peptide glucagon-like peptide-1 (GLP-1) and its role in glucose regulation paved the way for the class of GLP-1 receptor ...
Ji Hyun, Chun, Amy, Butts
openaire   +4 more sources

Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP‐1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta‐analysis

Rheumatology & Autoimmunity
Background In recent years, medications including sodium‐glucose cotransporter 2 inhibitors (SGLT2i), glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), angiotensin‐converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBs) have been
Jiarong Liu, Jixiong Xu
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review

BMC Musculoskeletal Disorders
Background Obesity and type 2 diabetes mellitus (T2DM) are associated with impaired rotator cuff tendon healing and inferior clinical outcomes following surgical repair.
Dave Osinachukwu Duru, Andrew Kailin Zhou, David Kwan Ryung Lee, Patrick J. Carroll, Amr Elmaraghy   +4 more
doaj   +1 more source

All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium–Glucose Cotransporter-2 Inhibitors

Gastro Hep Advances
Background and Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used in adults with type 2 diabetes (T2D), with or without obesity. The incidence of gastrointestinal (GI) adverse effects (AEs) of GLP-1RA in T2D is unclear.
Samita Garg, Thabet Qapaja, Osama Hamid, Gizem Kaya, Rashid Abdel-Razeq, Dina Alayan, Mohammed Abu-Rumaileh, Anthony Lembo, Steven Nissen   +8 more
doaj   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs

Biomedicines
Cardiovascular–Kidney–Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the liver—an organ fundamental to metabolic regulation.
Nikolaos Theodorakis, Maria Nikolaou
openaire   +3 more sources

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?

Acta Diabetologica, 2023
AbstractHyperglycemia strongly affects endothelial function and activation, which in turn increases the risk of atherosclerotic cardiovascular disease. Among pharmacotherapies aimed at lowering blood glucose levels, glucagon-like peptide 1 receptor agonists (GLP-1RA) represent a class of drugs involved in the improvement of the endothelium damage and ...
Rossella Menghini, Viviana Casagrande, Stefano Rizza, Massimo Federici   +3 more
openaire   +3 more sources

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

, 2022
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO-DKD trial (NCT02540993).
Bakris, George L., Lage, Andrea, Gerasimos, Scott, Charlie, Anker, Stefan D., Ruilope, Luis M., FIDELIO-DKD Investigators, Agarwal, Rajiv, Marre, Michel, Rossing, Peter, Filippatos, Pitt, Bertram, Amod, Aslam, Joseph, Amer   +13 more
core